- Home
- GHC vs ZLAB Comparison
GHC vs ZLAB Comparison
Compare GHC & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHC
- ZLAB
- Stock Information
- Founded
- GHC 1877
- ZLAB 2013
- Country
- GHC United States
- ZLAB China
- Employees
- GHC N/A
- ZLAB N/A
- Industry
- GHC Other Consumer Services
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- GHC Real Estate
- ZLAB Health Care
- Exchange
- GHC Nasdaq
- ZLAB Nasdaq
- Market Cap
- GHC 4.2B
- ZLAB 3.6B
- IPO Year
- GHC N/A
- ZLAB 2017
- Fundamental
- Price
- GHC $920.51
- ZLAB $32.54
- Analyst Decision
- GHC
- ZLAB Buy
- Analyst Count
- GHC 0
- ZLAB 5
- Target Price
- GHC N/A
- ZLAB $54.28
- AVG Volume (30 Days)
- GHC 65.6K
- ZLAB 782.4K
- Earning Date
- GHC 07-30-2025
- ZLAB 08-05-2025
- Dividend Yield
- GHC 0.78%
- ZLAB N/A
- EPS Growth
- GHC 134.95
- ZLAB N/A
- EPS
- GHC 141.53
- ZLAB N/A
- Revenue
- GHC $4,804,157,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- GHC $0.54
- ZLAB $44.07
- Revenue Next Year
- GHC $6.39
- ZLAB $49.13
- P/E Ratio
- GHC $6.51
- ZLAB N/A
- Revenue Growth
- GHC 5.91
- ZLAB 43.72
- 52 Week Low
- GHC $691.41
- ZLAB $16.01
- 52 Week High
- GHC $1,015.00
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- GHC 41.91
- ZLAB 40.19
- Support Level
- GHC $912.00
- ZLAB $34.26
- Resistance Level
- GHC $937.53
- ZLAB $35.72
- Average True Range (ATR)
- GHC 20.27
- ZLAB 1.12
- MACD
- GHC -3.96
- ZLAB -0.54
- Stochastic Oscillator
- GHC 12.47
- ZLAB 3.83
About GHC Graham Holdings Company
Graham Holdings Co. is a diversified education and media company made up of subsidiaries. Firm operations include educational services; television broadcasting; online, print, and local news; home health and hospice care; and manufacturing. The Company segments into the following seven reportable segments: Kaplan International, Higher Education, Supplemental Education, Television Broadcasting, Manufacturing, Healthcare, and Automotive. The majority of revenue comes from the Kaplan International segment, which includes higher education, test preparation, language instruction, and professional training. A large portion of company revenue also comes from the television broadcasting segment through advertising.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.